Prognostic Index of Shamash et al for Predicting the Response of a Patient with Castrate-Resistant Prostate Cancer to Dexamethasone and Diethylstilbesterol Therapy

Purpose: To identify a patient with prostate cancer who is likely to respond to dexamethasone and diethylstilbesterol based on the study of Shamash et al.

Info MyLikes MyPaths

Evaluation

Are you evaluating a patient with prostate cancer that is castrate-resistant?

Yes

Initial serum PSA

Serum PSA 1 month after starting dexa-methasone and diethylstilbesterol therapy

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Ratio of serum PSA 1 month after starting therapy to initial PSA

Total score

Risk group

Predicted overall 2-year survival

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
Severity, Prognosis, Stage

Specialty

Hematology Oncology
Surgery, general
Urology

Objective

severity
prognosis
stage

ICD-10

C61 - Malignant neoplasm of prostate

Info

Purpose: To identify a patient with prostate cancer who is likely to respond to dexamethasone and diethylstilbesterol based on the study of Shamash et al.

Specialty: Hematology Oncology, Surgery, general, Urology

Objective: severity, prognosis, stage

ICD-10: C61,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path